JPRN-UMIN000007202
Completed
未知
A clinical study of a combination drug for type2 diabetes -Using self-monitoring of blood glucose and meal tolerance test- - A clinical study of a combination drug for type2 diabetes -Using self-monitoring of blood glucose and meal tolerance test
Advanced Clinical Research Organization0 sites10 target enrollmentFebruary 3, 2012
Conditionstype2 diabetes
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- type2 diabetes
- Sponsor
- Advanced Clinical Research Organization
- Enrollment
- 10
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Patients who are applicable to the \[taboo issue] in a package insert of Glubes combination tablets. Patients who have severe ketosis, precoma or diabetic coma or type 1 diabetes. Patients with severe infection or severe injury. Patients accepting surgery. Patients with a history of hypersensitivity to any component of this drug. Pregnant women and women suspected to be pregnant. 2\) Patients whom the principal investigator and investigators decided not to be appropriate for taking Glubes combination tablets, on the point of \[Special caution needed] and \[side effects] in the package insert.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A clinical study of combination drug against type 2 diabetes - Glubes combination tablets for patients poorly controlled with a-GI or Glinidetype2 diabetesJPRN-UMIN000007203Advanced Clinical Research Organization30
Active, not recruiting
Not Applicable
A phase II clinical trial on the combination of dabrafenib and trametinib for BRAF-inhibitor pretreated patients with advanced BRAF V600 mutant melanomaadvanced BRAF V600 mutant melanomaMedDRA version: 16.1Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: HLTClassification code 10027156Term: Skin melanomas (excl ocular)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10066600Term: Melanoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10027480Term: Metastatic malignant melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-004966-33-BEZ Brussel
Completed
Phase 2
Phase II clinical study of the combination chemotherapy regimen of topotecan plus oral etoposide for the treatment of recurrent ovarian cancerResistant ovarian cancerJPRN-UMIN000007318Kyorin University, School of Medicine20
Not yet recruiting
Phase 4
Study for Tong-Mai Yang-Xin pill for delaying the myocardial reconstruction after PCI operation of coronary heart diseaseITMCTR1900002321The First Affiliated Hospital of He'nan University of CM
Active, not recruiting
Not Applicable
Clinical trial to evaluate the treatment with a drug (lenalidomide) with the usually prescribed chemotherapy in patients diagnosed with diffuse large B-cell lymphoma (sort of blood cancer) which did not respond to previous treatments and who can not receive high-dose chemotherapy.EUCTR2014-001620-29-ESGrupo Español para el Tratamiento y Estudio de los Linfomas (GOTEL)77